Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Solid Dispersion of an HIV Protease Inhibitor

  • Received : 2011.03.08
  • Accepted : 2011.04.01
  • Published : 2011.04.20
Download PDF
⟨ Previous Next ⟩

Abstract

LB71350 is an HIV protease inhibitor with poor aqueous solubility and extensive first pass effect. The purpose of the present study was to test the feasibility of solid dosage form of LB71350 with improved bioavailability utilizing solid dispersion. Three different compositions with varying ratio of (LB71350: Gelucire 44/14: Tween 20) were studied. Capsule filling of these solid dispersion compositions was tested using a semi-automatic capsule filling system. Oral bioavailability in dog was tested. Chemical and physical stability at 4, 25 and $40^{\circ}C$ was monitored by HPLC assay, dissolution test, powder XRD and microscopy. The capsule filling system yielded uniform products of drug loading up to 10%. Oral bioavailability in dog was improved compared to the aqueous suspension of crystalline LB71350. Capsules were chemically stable for up to 6 months at $40^{\circ}C$. However, there were temperature and composition dependent physical changes. Decrease in dissolution rates after storage at $40^{\circ}C$ was due to the polymorphic change. In conclusion, manufacturing process, bioavailability, and physico-chemical stability have been considered to propose a solid dispersion capsule formulation for the HIV protease inhibitor with poor physico-chemical properties. A new less soluble crystalline form identified during the physical stability test warrants further study.

Keywords

References

  1. Aungst, B.J., Nguyen, N.H., Rogers, N.J., Rowe, S.M., Hussain, M.A., White, S.J., Shum, L., 1997. Amphiphilic vehicles improve the oral bioavailability of a poorly soluble HIV protease inhibitor at high doses. Int. J. Pharm., 156, 79-88. https://doi.org/10.1016/S0378-5173(97)00189-0
  2. Beckmann, W., Otto, W.H., 1996. Occurrence, stability, kinetics of crystallization and polymorphic transition of the A, B and C modification of Abecarnil: Influence of Supersaturation, Temperature, Solvents and Impurities. Chem. Eng. Res. Des., Part A, 74, 750-758.
  3. Byrn, S., Pfeiffer, R., Ganey, M.; Hoiberg, C., Poochikian., G., 1995. Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations. Pharm. Res., 12, 945-954. https://doi.org/10.1023/A:1016241927429
  4. Byrn, S., Pfeiffer, R., Stowell, J., 1999. Solid-state chemistry of drugs, 2nd Ed., SSCI, Inc., West Lafayette, pp. 261-278.
  5. Cole E.T., Cade D., Benameur H., 2008. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration. Adv. Drug Del. Rev 60, 747-756. https://doi.org/10.1016/j.addr.2007.09.009
  6. Curatolo, W., 1998. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm. Sci. Technol. Today., 1(9) 387-393. https://doi.org/10.1016/S1461-5347(98)00097-2
  7. Hauss D.J. 2007. Oral lipid-based formulations. Adv. Drug Del. Rev., 59, 667-676. https://doi.org/10.1016/j.addr.2007.05.006
  8. Horter, D., Dressman, J.B., 1997. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug. Del. Rev., 25, 3-14. https://doi.org/10.1016/S0169-409X(96)00487-5
  9. Jeong, Y.-N., Seo, M.-K., Lee, S.-H., Choi, Y.-J., Kim, I.-C., Lee, Y.-H., 1996. Pharmacokinetics of the irreversible HIV-1 protease inhibitor, LB71350, in rats and dogs. Pharm. Res., 13, S-486.
  10. Jeong, Y.-N., Seo, M.-K., Choi, Y.-J., Kim, I.-C., Lee, Y.-H., 1997. High-performance liquid chromatographic assay of a new HIV-1 protease inhibitor, LB71350, in the plasma of dogs. J. Chromatogr. Biomed. Sci. Appl., 703, 284-288. https://doi.org/10.1016/S0378-4347(97)00395-2
  11. Joshi, H.N., Tejwani, R.W., Davidovich, M., Sahasrabudhe, V.P., Jemal, M., Bathala, M.S., Varia, S.A. and Serajuddin, A.T.M. 2004. Bioavailability enhancement of a pooly water -soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture. Int. J. Pharm. 269, 251-258 https://doi.org/10.1016/j.ijpharm.2003.09.002
  12. Lee, H.-K., Cho, H., Han, H.-K., 2010. Improved dissolution of poorly water soluble TD49, a novel algicidal agent, via the preparation of solid dispersion. J. Pharm. Invest. 40(3), 181-185. https://doi.org/10.4333/KPS.2010.40.3.181
  13. Leuner, C., Dressman, J., 2000. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm., 50, 47-60. https://doi.org/10.1016/S0939-6411(00)00076-X
  14. Lipinski, C.A., 2000. Drug-like properties and the cause of poor solubility and poor permeabiloity. J. Pharmacol. Toxicol. Methods, 44, 235-249. https://doi.org/10.1016/S1056-8719(00)00107-6
  15. Saleki-Gehardt, A., Ahlneck, C., Zografi, G., 1994. Assessment of disorder in crystalline solids. Int. J. Pharm., 101, 237-247. https://doi.org/10.1016/0378-5173(94)90219-4
  16. Serajuddin, A.T.M., Sheen, P.-C., Mufson, D., Bernstein, D.F., Augustine, M.A., 1988. Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersions. J. Pharm. Sci., 77, 414-417. https://doi.org/10.1002/jps.2600770512
  17. Strickley R.G. 2004. Solubilizing excipients in oral and injectible formulations. Pharm. Res. 21(2) 201-230. https://doi.org/10.1023/B:PHAM.0000016235.32639.23
  18. Stegemann, S., Leveiller, F. Franchi, D., de Jong H., Linden, H., 2007. When poor solubility becomes an issue: From early stage to proof of concept. Eur. J. Pharm. Sci. 31, 249-261. https://doi.org/10.1016/j.ejps.2007.05.110
  19. Sugimoto, M., Okagaki, T., Narisawa, S., Koida, Y., Nakajima, K., 1998. Improvement of dissolution characteristics and bioavailability of poorly water-soluble drugs by novel cogrinding method using water-soluble polymer. Int. J. Pharm., 160, 11-19. https://doi.org/10.1016/S0378-5173(97)00293-7
  20. Suryanarayanan, R., 1995. Physical Chracterization of Pharmaceutical Solids, 2nd Ed.: Brittain, H.G. (Ed.), Drugs and the pharmaceutical sciences, Vol. 70, Dekker, New York, pp. 187-221.
  21. Vasconcelos, T., Sarmento B., Costa P., Solid dispersion as strategy to improve orall bioavailability of poor water soluble drugs. 2007. Drug Discovery Today, 12 (23/24) 1068-1075. https://doi.org/10.1016/j.drudis.2007.09.005
  22. Waynforth, H.B., 1995. Laboratory animals: An introduction for experimenters, 2nd Ed: Tuffery, A.A. (Ed.), Wiley, New York, pp. 304-306.
  23. Yamada, T., Saito, N., Anraku, M., Imai, T., Otagiri, M., 2000. Physicochemical Characterization of a new crystal form and improvements in the pharmaceutical properties of the poorly water-soluble antiosteoporosis drug 3,9-bis(N,N-dimethylcarbamoy-loxy)-5H-benzofuro[3,2-c]quinoline-6-one (KCA-098) by solid dispersion with hydroxypropylcelluose. Pharm. Dev. Technol., 5, 443-454. https://doi.org/10.1081/PDT-100102028